What is Currently the Best for Adenocarcinoma without Driver Mutation?

Схожие документы

• Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
  по: Choi, Hayoung, et al.
  Опубликовано: (2015)
• Superior vena cava syndrome with extensive collateral vessels
  по: Oh, In‐Jae, et al.
  Опубликовано: (2019)
• Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma Without Driver Mutation
  по: Minami, Seigo, et al.
  Опубликовано: (2018)
• Percutaneous biopsy of abdominal lesions: what is currently the best diagnostic strategy?
  по: Nunes, Thiago Franchi
  Опубликовано: (2018)
• A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
  по: Park, Cheol-Kyu, et al.
  Опубликовано: (2021)